Aprea Therapeutics Inc APRE shares are trading higher after the company announced that it received FDA Orphan Drug Designation for its eprenetapopt for the treatment of acute myeloid leukemia.
Aprea Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing cancer therapeutics. Its product candidate, APR-246, is a small molecule p53 reactivator that is in late-stage clinical development for hematologic malignancies, including myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML).
Immutep Ltd IMMP shares are trading higher after the company announced it received fast track designation from the FDA for its Efti to soluble lag-3 protein in the first line of recurrent and metastatic head and neck cancer.
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases.
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
